{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:46:48Z","timestamp":1793119608400,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.transproceed.2019.08.044","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T01:27:30Z","timestamp":1573694850000},"page":"3437-3443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation"],"prefix":"10.1016","volume":"51","author":[{"given":"Shun","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maasa","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Watanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kabasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Uto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Nakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2019.08.044_bib1","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2019.08.044_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2019.08.044_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-144-6-200603210-00007","article-title":"A\u00a0risk score for mortality after allogeneic hematopoietic cell transplantation","volume":"144","author":"Parimon","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transproceed.2019.08.044_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A\u00a0disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2019.08.044_bib5","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2019.08.044_bib6","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbmt.2018.05.007","article-title":"Status of natural killer cell recovery in day 21 bone marrow after allogeneic hematopoietic stem cell transplantation predicts clinical outcome","volume":"24","author":"Hattori","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2019.08.044_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2019.01.013","article-title":"Monitoring TIGIT\/DNAM-1 and PVR\/pvrl2 immune checkpoint expression levels in allogeneic stem cell transplantation for acute myeloid leukemia","volume":"25","author":"Hattori","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2019.08.044_bib8","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose post-transplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2019.08.044_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/bmt.2016.286","article-title":"An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication","volume":"52","author":"Maka","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2019.08.044_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjh.14962","article-title":"Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies","volume":"179","author":"Paviglianiti","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transproceed.2019.08.044_bib11","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood-2014-10-551465","article-title":"How I treat mixed-phenotype acute leukemia","volume":"125","author":"Wolach","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2019.08.044_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjh.12484","article-title":"Cytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview","volume":"163","author":"Manola","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transproceed.2019.08.044_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00277-013-1694-4","article-title":"Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization","volume":"92","author":"Heesch","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transproceed.2019.08.044_bib14","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2019.08.044_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ejh.12516","article-title":"Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis","volume":"95","author":"Shimizu","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transproceed.2019.08.044_bib16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.bbmt.2016.02.013","article-title":"Center for International Blood and Marrow Transplant Research. Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia","volume":"22","author":"Munker","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2019.08.044_bib17","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2019.08.044_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/bmt.2008.39","article-title":"Graft-versus-adult T-cell leukemia\/lymphoma effect following allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Yonekura","year":"2008","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519309479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519309479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:33:12Z","timestamp":1758576792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134519309479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0041134519309479"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.08.044","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}